BACK TO CONTENTS   |    PDF   |    PREVIOUS   |    NEXT

Title

Nilotinib based pharmacophore models for BCR-ABL

 

Authors

Kesavan Sabitha

 

Affiliation

Department of Bioinformatics, Guru Nanak College, Velacherry, Chennai-600 036

 

Email

rk_sabitha@yahoo.co.in; *Corresponding author

 

Article Type

Hypothesis

 

Date

Received June 25, 2012; Accepted July 05, 2012; Published July 21, 2012

 

Abstract

Tyrosine kinase inhibitors have revolutionized the treatment of several malignancies, converting lethal diseases in a manageable aspect. Imitanib, a small molecule ABL kinase inhibitor is a highly effective therapy for early phase chronic myeloid leukemia (CML), which has constitutively active ABL kinase activity owing to the over expression of the BCR-ABL fusion protein. But some patients develop imatinib resistance, particularly in the advanced phases of CML.The discovery of resistance mechanisms of imitanib; urge forward the development of second generation drugs. Nilotinib, a second generation drug is more potent inhibitor of BCR-ABL than imatinib. But nilotinib also develops dermatologic events and headache in patients. Large information about BCR-ABL structure and its inhibitors are now available. Based on the pharmacophore modeling approaches, it is possible to decipher the molecular determinants to inhibit BCR-ABL. We conducted a structure based and ligand based study to identify potent natural compounds as BCR-ABL inhibitor. First kinase inhibitors were docked with the receptor (BCR-ABL) and nilotinib was selected as a pharmacophore due its high binding efficiency. Eleven compounds were selected out of 1457 substances which have mutual pharmacopohre features with nilotinib. These eleven compounds were validated and used for docking study to find the drug like molecules. The best molecules from the final set of screening candidates can be evaluated in cell lines and may represent a novel class of BCR-ABL inhibitors.

 

Keywords

Ligand docking, BCR-ABL, Nilotinib, Glide score, Pharmacophore modeling

Citation

Sabitha, Bioinformation 8(14): 658-663 (2012)
 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.